Coronary Revascularization in Patients With Cancer.

Autor: Pushparaji B; Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY USA., Donisan T; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN USA., Balanescu DV; Department of Internal Medicine, Beaumont Hospital, Royal Oak, Rochester, MI USA., Park JK; Deparment of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX USA., Monlezun DJ; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA., Ali A; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA., Inanc IH; Department of Cardiology, Kirikkale Research and Training Hospital, Kirikkale, Turkey., Caballero J; Interventional Cardiology, Department of Internal Medicine, University of South Florida, Tampa, FL USA., Cilingiroglu M; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA., Marmagkiolis K; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA., Iliescu C; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Jazyk: angličtina
Zdroj: Current treatment options in cardiovascular medicine [Curr Treat Options Cardiovasc Med] 2023; Vol. 25 (6), pp. 143-158. Date of Electronic Publication: 2023 Apr 21.
DOI: 10.1007/s11936-023-00982-9
Abstrakt: Purpose of Review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage.
Recent Findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing.
Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology - Cardio-oncology guidelines in 2022.
Competing Interests: Conflict of InterestBala Pushparaji declares that he has no conflict of interest. Teodora Donisan declares that she has no conflict of interest. Dinu Valentin Balanescu declares that he has no conflict of interest. Jong Kun Park declares that he has no conflict of interest. Dominique J. Monlezun declares that he has no conflict of interest. Abdelrahman Ali declares that he has no conflict of interest. Ibrahim Halil Inanc declares that he has no conflict of interest. Jaime Caballero declares that he has no conflict of interest. Mehmet Cilingiroglu declares that he has no conflict of interest. Konstantinos Marmagkiolis declares that he has no conflict of interest. Cezar Iliescu declares that he has no conflict of interest.
(© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: